Array Bridge is testing promising drug candidates that can effectively bind and even degrade target proteins, but not via ...

The deal – which is worth up to $905 million with an upfront fee of $90 million – gives BMS full control of BridgeBio's experimental SHP2 inhibitor BBP-398, which is already in a phase 1 trial ...